CXCR4

C-X-C chemokine receptor type 4 · P61073 · CXCR4 on Sugi Atlas →

61,086 patent compounds predicted against CXCR4, 35,186 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Plerixafor Plerixafor (SCHEMBL19038) 1.00 16/20
Plerixafor Plerixafor (SCHEMBL123040) 1.00 16/20
Plerixafor Plerixafor (SCHEMBL414153) 1.00 16/20
SCHEMBL674043 SCHEMBL674043 0.83 16/20
SCHEMBL688144 SCHEMBL688144 0.77 16/20
SCHEMBL674057 SCHEMBL674057 0.68 16/20
SCHEMBL673928 SCHEMBL673928 0.63 16/20
SCHEMBL673242 SCHEMBL673242 0.61 16/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL209072) 0.78 15/20
SCHEMBL674945 SCHEMBL674945 0.75 15/20
SCHEMBL674927 SCHEMBL674927 0.65 15/20
SCHEMBL674657 SCHEMBL674657 0.83 14/20
SCHEMBL599000 SCHEMBL599000 1.00 13/20
SCHEMBL674069 SCHEMBL674069 1.00 13/20
SCHEMBL673249 SCHEMBL673249 0.86 13/20
SCHEMBL255099 SCHEMBL255099 0.77 13/20
SCHEMBL675122 SCHEMBL675122 0.60 13/20
SCHEMBL608319 SCHEMBL608319 0.52 13/20
SCHEMBL681346 SCHEMBL681346 0.52 13/20
SCHEMBL64922 SCHEMBL64922 0.50 13/20

Clinical trials — most relevant to CXCR4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia PHASE3COMPLETED
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome PHASE2/PHASE3COMPLETED
Gallium-68 Labeled Pentixafor PET/CT in Adrenal Masses PHASE2/PHASE3UNKNOWN
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma PHASE1/PHASE2COMPLETED
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma PHASE2COMPLETED
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... PHASE1/PHASE2RECRUITING
Quantitating the Impact of Plerixafor PHASE1/PHASE2UNKNOWN
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission PHASE2UNKNOWN
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma PHASE1COMPLETED
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients PHASE1COMPLETED
U69-CART-Cells For R/R T-ALL PHASE1RECRUITING
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study EARLY_PHASE1RECRUITING
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma EARLY_PHASE1UNKNOWN
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases EARLY_PHASE1UNKNOWN
Application of 68Ga-Pentixafor PET/CT for Thymoma EARLY_PHASE1UNKNOWN
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases nanRECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease nanCOMPLETED
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients nanRECRUITING
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma nanUNKNOWN
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing ThroughMarrow-Blood Barrier nanUNKNOWN
The Role of Cxcr4Hi neutrOPhils in InflueNza nanRECRUITING
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma nanCOMPLETED
Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CXCR4 binder may also engage these)

ProteinNameSimilarity
Q9TSQ8 1.000 Q9TSQ8 →
P79394 1.000 P79394 →
P61072 1.000 P61072 →
Q3LSL6 1.000 Q3LSL6 →
P56491 1.000 P56491 →
P56498 1.000 P56498 →
Q28474 1.000 Q28474 →
Q7YS92 1.000 Q7YS92 →
P25930 1.000 P25930 →
Q8HZU1 1.000 Q8HZU1 →
Q9YGC3 1.000 Q9YGC3 →
Q07FZ4 1.000 Q07FZ4 →
Q7ZXJ7 1.000 Q7ZXJ7 →
O62747 1.000 O62747 →
P70658 1.000 P70658 →
Q8HZU0 1.000 Q8HZU0 →
O08565 1.000 O08565 →
Q764M9 1.000 Q764M9 →
P35350 0.998 P35350 →
P79785 0.998 P79785 →
Q9N0Z0 0.998 Q9N0Z0 →
Q9Z2I3 0.997 Q9Z2I3 →
Q924I3 0.996 Q924I3 →
Q95NC6 0.996 Q95NC6 →
Q95NC4 0.996 Q95NC4 →
P35411 0.996 P35411 →
Q95NC2 0.996 Q95NC2 →
Q9XT45 0.996 Q9XT45 →
O18983 0.996 O18983 →
Q95NC0 0.996 Q95NC0 →